An Overview of Gaucher Disease

Background: Gaucher disease (GD) is a rare autosomal recessive disorder caused by mutations in the GBA1 gene that lead to a deficiency in the glucocerebrosidase gene. This deficiency results in the accumulation of glucocerebrosides in macrophages, primarily affecting the liver, spleen, and bone marr...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniela Anahí Méndez-Cobián, Sandra Guzmán-Silahua, Diana García-Hernández, Julian Conde-Sánchez, Yaocihuatl Castañeda-Borrayo, Kylee Louise Duey, Maria G. Zavala-Cerna, Benjamín Rubio-Jurado, Arnulfo Hernán Nava-Zavala
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/14/24/2840
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850241433106120704
author Daniela Anahí Méndez-Cobián
Sandra Guzmán-Silahua
Diana García-Hernández
Julian Conde-Sánchez
Yaocihuatl Castañeda-Borrayo
Kylee Louise Duey
Maria G. Zavala-Cerna
Benjamín Rubio-Jurado
Arnulfo Hernán Nava-Zavala
author_facet Daniela Anahí Méndez-Cobián
Sandra Guzmán-Silahua
Diana García-Hernández
Julian Conde-Sánchez
Yaocihuatl Castañeda-Borrayo
Kylee Louise Duey
Maria G. Zavala-Cerna
Benjamín Rubio-Jurado
Arnulfo Hernán Nava-Zavala
author_sort Daniela Anahí Méndez-Cobián
collection DOAJ
description Background: Gaucher disease (GD) is a rare autosomal recessive disorder caused by mutations in the GBA1 gene that lead to a deficiency in the glucocerebrosidase gene. This deficiency results in the accumulation of glucocerebrosides in macrophages, primarily affecting the liver, spleen, and bone marrow. Focusing on the Mexican population, this study aims to review GD’s epidemiology, clinical manifestations, and treatment options to enhance early diagnosis and optimize treatment outcomes. Methods: This study is a comprehensive literature review analyzing epidemiological data, clinical presentations, and current therapeutic approaches for Gaucher disease, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Conclusions: Early diagnosis and individualized treatment, primarily through enzyme replacement therapy, significantly improve the prognosis of patients with Gaucher disease, particularly type 1. Continued research is required to enhance therapeutic approaches for the neuropathic types and better understand the disease’s epidemiology in Mexico. These efforts will contribute to improved clinical outcomes and quality of life for patients.
format Article
id doaj-art-8031d48b9ac540639df0b25cd40ad91e
institution OA Journals
issn 2075-4418
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj-art-8031d48b9ac540639df0b25cd40ad91e2025-08-20T02:00:37ZengMDPI AGDiagnostics2075-44182024-12-011424284010.3390/diagnostics14242840An Overview of Gaucher DiseaseDaniela Anahí Méndez-Cobián0Sandra Guzmán-Silahua1Diana García-Hernández2Julian Conde-Sánchez3Yaocihuatl Castañeda-Borrayo4Kylee Louise Duey5Maria G. Zavala-Cerna6Benjamín Rubio-Jurado7Arnulfo Hernán Nava-Zavala8Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoUnidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoUnidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoUnidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoUnidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoSchool of Medicine International Program, Universidad Autónoma de Guadalajara, Av. Patria 1201, Zapopan 45129, Jalisco, MexicoImmunology Research Laboratory, Decanato Medicina, Universidad Autónoma de Guadalajara, Zapopan 45129, Jalisco, MexicoUnidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoUnidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, MexicoBackground: Gaucher disease (GD) is a rare autosomal recessive disorder caused by mutations in the GBA1 gene that lead to a deficiency in the glucocerebrosidase gene. This deficiency results in the accumulation of glucocerebrosides in macrophages, primarily affecting the liver, spleen, and bone marrow. Focusing on the Mexican population, this study aims to review GD’s epidemiology, clinical manifestations, and treatment options to enhance early diagnosis and optimize treatment outcomes. Methods: This study is a comprehensive literature review analyzing epidemiological data, clinical presentations, and current therapeutic approaches for Gaucher disease, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Conclusions: Early diagnosis and individualized treatment, primarily through enzyme replacement therapy, significantly improve the prognosis of patients with Gaucher disease, particularly type 1. Continued research is required to enhance therapeutic approaches for the neuropathic types and better understand the disease’s epidemiology in Mexico. These efforts will contribute to improved clinical outcomes and quality of life for patients.https://www.mdpi.com/2075-4418/14/24/2840Gaucher diseasehereditary diseaselysosomal storage diseasestreatment
spellingShingle Daniela Anahí Méndez-Cobián
Sandra Guzmán-Silahua
Diana García-Hernández
Julian Conde-Sánchez
Yaocihuatl Castañeda-Borrayo
Kylee Louise Duey
Maria G. Zavala-Cerna
Benjamín Rubio-Jurado
Arnulfo Hernán Nava-Zavala
An Overview of Gaucher Disease
Diagnostics
Gaucher disease
hereditary disease
lysosomal storage diseases
treatment
title An Overview of Gaucher Disease
title_full An Overview of Gaucher Disease
title_fullStr An Overview of Gaucher Disease
title_full_unstemmed An Overview of Gaucher Disease
title_short An Overview of Gaucher Disease
title_sort overview of gaucher disease
topic Gaucher disease
hereditary disease
lysosomal storage diseases
treatment
url https://www.mdpi.com/2075-4418/14/24/2840
work_keys_str_mv AT danielaanahimendezcobian anoverviewofgaucherdisease
AT sandraguzmansilahua anoverviewofgaucherdisease
AT dianagarciahernandez anoverviewofgaucherdisease
AT juliancondesanchez anoverviewofgaucherdisease
AT yaocihuatlcastanedaborrayo anoverviewofgaucherdisease
AT kyleelouiseduey anoverviewofgaucherdisease
AT mariagzavalacerna anoverviewofgaucherdisease
AT benjaminrubiojurado anoverviewofgaucherdisease
AT arnulfohernannavazavala anoverviewofgaucherdisease
AT danielaanahimendezcobian overviewofgaucherdisease
AT sandraguzmansilahua overviewofgaucherdisease
AT dianagarciahernandez overviewofgaucherdisease
AT juliancondesanchez overviewofgaucherdisease
AT yaocihuatlcastanedaborrayo overviewofgaucherdisease
AT kyleelouiseduey overviewofgaucherdisease
AT mariagzavalacerna overviewofgaucherdisease
AT benjaminrubiojurado overviewofgaucherdisease
AT arnulfohernannavazavala overviewofgaucherdisease